Superior outcome of infant acute myeloid leukemia with intensive chemotherapy: results of the Japan Infant Leukemia Study Group.
This study analyzed data on 35 infants with acute myeloid leukemia (AML) who were treated with intensive chemotherapy between 1995 and 1998 in Japan. The incidence of boys, younger age (< 6 months old), and hyperleukocytosis at onset was high in patients with the M4/M5 subtype (n = 23) in the French-American-British classification, compared with the non-M4/M5 subtype (n = 12). Thirteen (56%) and 16 (70%) patients with the M4/M5 subtype also showed 11q23 translocations and MLL gene rearrangements, respectively, whereas only one patient with the non-M4/M5 subtype had this rearrangement. All 35 patients were treated with the ANLL91 protocol consisting of etoposide, high-dose cytarabine, and anthracyclines. Overall survival and the event-free survival (EFS) rates at 3 years of all patients were 76% (95% confidence interval [CI], 61.3%-90.7%) and 72% (95% CI, 56.4%-87.9%), respectively. EFS showed no significant difference between 2 subgroups divided by age, gender, presence of the MLL gene rearrangements, and white blood cell count at onset; EFS in patients with the M4/M5 subtype tended to be better than those with the non-M4/M5 subtype. Although all 6 patients who underwent allogeneic stem cell transplantation (SCT) have been in complete remission, no benefit of SCT was confirmed. These findings suggest that the intensive chemotherapy with the ANLL91 protocol might have been responsible for the observed good outcome of infant AML, even without SCT. The presence of the MLL gene rearrangements or the age at onset had no impact on the outcome of infant AML.
Kawasaki
H
H
Department of Pediatrics, Mie University, Japan.
Isoyama
K
K
Eguchi
M
M
Hibi
S
S
Kinukawa
N
N
Kosaka
Y
Y
Oda
T
T
Oda
M
M
Nishimura
S
S
Imaizumi
M
M
Okamura
T
T
Hongo
T
T
Okawa
H
H
Mizutani
S
S
Hayashi
Y
Y
Tsukimoto
I
I
Kamada
N
N
Ishii
E
E
D015250:Aclarubicin / Q000008:administration & dosage; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects*; D002880:Chromosomes, Human, Pair 11; D003561:Cytarabine / Q000008:administration & dosage* / Q000009:adverse effects*; D004268:DNA-Binding Proteins / Q000235:genetics; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives; D005047:Etoposide / Q000008:administration & dosage* / Q000009:adverse effects*; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D011495:Histone-Lysine N-Methyltransferase; D006801:Humans; D016130:Immunophenotyping; D007223:Infant; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D008297:Male; D008942:Mitoxantrone / Q000008:administration & dosage; D051788:Myeloid-Lymphoid Leukemia Protein; D011379:Prognosis; D011519:Proto-Oncogenes; D012074:Remission Induction; D015996:Survival Rate; D014157:Transcription Factors; D014178:Translocation, Genetic; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
D000903:Antibiotics, Antineoplastic; D004268:DNA-Binding Proteins; C497422:KMT2A protein, human; D014157:Transcription Factors; D003561:Cytarabine; D051788:Myeloid-Lymphoid Leukemia Protein; D014750:Vincristine; D005047:Etoposide; D015250:Aclarubicin; D004317:Doxorubicin; D008942:Mitoxantrone; C027260:pirarubicin; D011495:Histone-Lysine N-Methyltransferase